A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (PASS)
Clinical Trial Grant
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Genzyme Corporation
Start Date
November 18, 2016
End Date
December 31, 2028
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Genzyme Corporation
Start Date
November 18, 2016
End Date
December 31, 2028